A Single-Dose, Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Pharmacokinetics of Abiraterone in Chinese Healthy Male Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Congenital adrenal hyperplasia; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 13 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Sep 2012 New trial record